Facinicline

Drug Profile

Facinicline

Alternative Names: MEM-63908; R-4996

Latest Information Update: 30 Mar 2010

Price : $50

At a glance

  • Originator Memory Pharmaceuticals
  • Developer Roche
  • Class Antidementias; Nootropics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 30 Mar 2010 No development reported - Phase-I for Alzheimer's disease in Canada (PO)
  • 19 Dec 2008 Adverse events and pharmacokinetic data from phase I trials Alzheimer's disease released by Memory Pharmaceuticlas
  • 26 Sep 2008 Memory Pharmaceuticals completes its phase I trial programme in Alzheimer's disease in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top